chronic kidney disease money
Biotech

Akebia promises $12M for Q32’s rare kidney disease candidate

Akebia has struck a deal for Q32's complement inhibitor ADX-097, bagging an asset that forms the centerpiece of its new rare kidney disease pipeline.
Nick Paul Taylor Dec 1, 2025 9:45pm
The Disposable Blind Spot Is Your Risk Strategy Keeping Pace with Single-Use Tech

The Disposable Blind Spot: Is Your Risk Strategy Keeping Pace with Single-Use Tech?

Dec 1, 2025 8:00am
Agentic AI concept

FDA adopts agentic AI in latest artificial intelligence push

Dec 1, 2025 5:33pm
Sites and Patients Fierce Article v2png

Meeting patients where they are: tailored support to drive recruitment and retention

Dec 1, 2025 8:00am
Rome forum Europe

EU, Angelini team up to funnel €150M to European health startups

Dec 1, 2025 2:02pm
Graphic of two hands shaking under a red and purple light

Regeneron inks $150M pact with gene writer Tessera

Dec 1, 2025 11:12am
More News

Chronic stress you can see—on a CT scan

Dec 1, 2025 10:40am

GE HealthCare, Philips, Siemens spotlight AI imaging at RSNA

Dec 1, 2025 9:15am

Belite brings FDA filing into view with phase 3 Stargardt win

Dec 1, 2025 8:25am

Protego tucks $130M series B into its fold

Dec 1, 2025 6:00am